|
| Wednesday, 16 August 2023, 08:00 HKT/SGT | |
| |
|
|
|
HONG KONG, Aug 16, 2023 - (ACN Newswire) - Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced on 15th that the Group plans to further subscribe for the shares of Taiko Pharmaceutical Co., Ltd. ("Taiko Pharmaceutical," stock code: 4574.JP) at a price of 338.58 yen per share (equivalent to approximately 18.35 Hong Kong dollars). The additional subscription will involve 1,007,500 shares of Taiko Pharmaceutical and representing approximately 2.08% of the enlarged issued share capital of Taiko Pharmaceutical. The total consideration for this transaction value amounts to 341,119,350 yen (equivalent to approximately 18,488,669 Hong Kong dollars). After this acquisition, combined with the previously subscribed shares, the group will collectively totally hold 3,185,900 shares of Taiko Pharmaceutical, representing approximately 6.42% of the enlarged issued share capital of Taiko Pharmaceutical.
Established in 1946, Taiko Pharmaceutical is a renowned pharmaceutical company in Japan, specializing in manufacturing and sales of pharmaceutical products and infection management (sanitation control) products. A key asset of its portfolio is the famous and long-standing, "Taiko Seirogan" brand, renowned for its effectiveness and over 120 years of history. Since its establishment in 1996, Kingworld Medicine has been the sole general distributor of the Taiko Seirogan in China, significantly contributing to expanding the domestic sales volume of Taiko Seirogan. Notably, in the past two years, there has been a significant 64% domestic market growth in 2022. Over time, Taiko Seirogan has become one of the best-selling flagship product of the Group.
As a leading enterprise in the field of greater health dedicated to the import and distribution of branded pharmaceutical and healthcare products, the Group remains committed to investing in the pharmaceutical and health industry. The increased stake in Taiko aligns with the Group's Fifth Five-Year strategic plan and operational objectives. The Group will continue consolidating its existing business and actively expand its upstream supply chain traceability cooperation with partners such as Hong Kong Foci Pharmaceutical Co., Ltd. and Taiko Pharmaceutical. The Group will focus on building the Longde health industry ecosystem to establish a comprehensive supply chain system within the pharmaceutical and greater health industry, expanding the Group's industry footprint.
Mr. Zhao Lisheng, Chairman of Kingworld Medicines Group, stated, "After Kingworld Medicines Group acquired a stake in Taiko Pharmaceutical in April this year, synergies between the two parties have enhanced operational quality and efficiency. The Group is committed to deepening cooperation with Taiko Pharmaceutical and leveraging this additional subscription to foster mutual growth. After the acquisition, the Group will continue to strengthen its position in the market for Taiko Seirogan, consolidating its brand presence. In the future, the Group will also explore related resources of Japanese herbal medicine to enrich the company's product portfolio and cultivate new avenues for profit growth. Therefore, investing in Taiko Pharmaceutical will assist the company in optimizing its industry layout, preserving and promoting traditional Chinese medicine formulations, and ultimately contributing to public health advancement."
Furthermore, in 2021, Kingworld Medicines invested a 49% stake in and operated Foci Hong Kong in partnership with Lanzhou Foci. During the collaboration, the Minshan brand series of products within the Hong Kong market saw exceptional growth. In 2022, Kingworld Medicines Group acquired Innopharm in France, officially expanding its European market. This increased stake in Taiko Pharmaceutical propels the expansion of the Group's upstream supply chain, promoting strategic synergy across the industry chain and enhancing international brand competitiveness and sales scale.
Topic: Press release summary
Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform
Apr 2, 2026 06:00 HKT/SGT
|
|
|
JDE Peet's Goes Live with OMP's Unison Planning(TM), Accelerating Supply Chain Value at Scale
Apr 1, 2026 21:50 HKT/SGT
|
|
|
Honda Makes Gachaco a Consolidated Subsidiary by Subscribing to New Shares of Gachaco Issued Through Third-party Allotment
Wednesday, April 1, 2026 9:09:00 PM
|
|
|
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
Apr 1, 2026 21:00 HKT/SGT
|
|
|
DENSO Hosted "DENSO DIALOG DAY 2026", Delivers Mid-Term Management Plan "CORE 2030"
Wednesday, April 1, 2026 8:54:00 PM
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 18:52 HKT/SGT
|
|
|
True IDC Pushes "Security Economy", Breaking Ground on Mega Data Center in EEC with 77-Billion-Baht BOI Investment, Cementing Thailand's No. 1 Position 
Apr 1, 2026 18:50 HKT/SGT
|
|
|
China Risun (01907.HK) Reports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges
Apr 1, 2026 18:07 HKT/SGT
|
|
|
CTF Life Collaborates with the HKMC to Refer the Policy Reverse Mortgage Programme and the Reverse Mortgage Programme
Apr 1, 2026 16:20 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
